Crinetics Pharmaceuticals's quarterly market cap
increased
from Sep. 2025 ($3,937.92 Mil) to Dec. 2025 ($4,449.02 Mil) but then
declined
from Dec. 2025 ($4,449.02 Mil) to Mar. 2026 ($3,825.00 Mil).
Crinetics Pharmaceuticals's annual market cap
increased
from Dec. 2023 ($2,425.67 Mil) to Dec. 2024 ($4,751.31 Mil) but then
declined
from Dec. 2024 ($4,751.31 Mil) to Dec. 2025 ($4,449.02 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Crinetics Pharmaceuticals's Enterprise Value for Today is $7,593.15 Mil.
Crinetics Pharmaceuticals (NAS:CRNX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Crinetics Pharmaceuticals Market Cap Related Terms
Crinetics Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crinetics Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals (CRNX) has a Market Cap of $8,836.61 Mil as of Jul. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Crinetics Pharmaceuticals and its competitors. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #50 out of 1420 companies in the Biotechnology industry, placing it in the top 3.5%.
Is Crinetics Pharmaceuticals' Market Cap too high?
Crinetics Pharmaceuticals' current Market Cap is $8,836.61 Mil. The Biotechnology industry median Market Cap is 121.52. Crinetics Pharmaceuticals' value of $8,836.61 Mil is 7172% above this industry median. Based on the distribution chart, Crinetics Pharmaceuticals ranks #50 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crinetics Pharmaceuticals has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Market Cap compare to CPRX and NAMS?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #50 out of 1420 companies for Market Cap. This places Crinetics Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.52. Crinetics Pharmaceuticals' value of $8,836.61 Mil is 7172% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.52, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crinetics Pharmaceuticals's current Market Cap of $8,836.61 Mil is 7172% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Crinetics Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 121.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crinetics Pharmaceuticals's current Market Cap is $8,836.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (CRNX) is currently considered Possible Value Trap. The stock's GF Value™ is $724.66, compared to a current price of $83.45 — trading 88.5% below its estimated fair value. The current Market Cap is $8,836.61 Mil and 7172% above the Biotechnology industry median of 121.52. Crinetics Pharmaceuticals' overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Crinetics Pharmaceuticals (CRNX), the current Market Cap is $8,836.61 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crinetics Pharmaceuticals (CRNX) Overvalued in 2026?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued.
The current stock price of $83.45 is trading 88.5% below its estimated GF Value™ of $724.66.
GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CRNX:
Market Cap: $8,836.61 Mil
GF Value™: $724.66 vs. price of $83.45 (88.5% below fair value)
Industry Position: 7172% above the Biotechnology median (#50 of 1420)
No single metric tells the full story. See the CRNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
41GF Score
Get the complete analysis for CRNX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRNX has been successfully added to your 
